

Letter to the Editor

Infection control in burn patients: are fungal infections underestimated?

Manuel F Struck

Address: Burn Trauma Center, Bergmannstrost Hospital, Merseburger Str. 165, 06110 Halle (Saale), Germany

Email: Manuel F Struck - manuelstruck@web.de

Published: 9 October 2009

Received: 15 September 2009

Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine 2009, 17:51 doi:10.1186/1757-7241-17-51

Accepted: 9 October 2009

This article is available from: <http://www.sjtreem.com/content/17/1/51>

© 2009 Struck; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/2.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

With great interest, I read the paper of David J. Dries about recent developments, infection control and outcomes research in the management of burn injuries [1]. I have some comments about an important, however missing, topic in the paragraphs concerning infection control.

Dear Sir,

With great interest, I read the paper of David J. Dries about recent developments, infection control and outcomes research in the management of burn injuries [1]. I have some comments about an important, however missing, topic in the paragraphs concerning infection control.

Infectious complications and sepsis are still the most important reasons of mortality in burn centres. Therefore, not only bacterial infections should be considered as the source of infection. Fungal colonization and infection gain a rising importance in the management of sepsis in burn patients. Burn patients are at the highest risk for mycoses, even more than oncologic and transplant patients [2]. Due to compromised immune defence and large wound surfaces, burn patients are predisposed for acquiring fungal organisms. The broad use of topic and systemic antibiotic agents either as prophylaxis or in case of confirmed bacterial infection further facilitates the development of mycoses.

Recently, a certain dynamic in the epidemiology of fungal organisms has been observed. Non-albicans *Candida* species have been found to be increasingly resistant against common antimycotic substances. Additionally, other spe-

cies such as *Aspergillus* and Zygomycoses, with an aggressive and invasive growth pattern are more frequently observed. The diagnostic methods to identify mycoses are still poor and often specific to some organisms. Direct tissue biopsy is performed rarely and mostly in case of a justified suspicion. The growth of fungal cultures is unreliable and associated with considerable latency - sometimes too late for the clinician to initiate antimycotic therapy appropriately. Since burn patients usually present with SIRS symptoms, clinical warning signals may be masked or misleading to bacterial infection. The author correctly highlights the need for a re-evaluation of definitions of SIRS and sepsis, as previously published [3].

Risk factors for acquiring a fungal infection are greater burned total body surface area, increasing age, late surgical excision, central venous catheters, hyperglycaemic episodes, steroid treatment, long-term artificial ventilation and inhalation injury. Mortality of mycotic burn patients is associated with i.v.-antimycotics, the presence of fungaemia, multiple positive cultures and invasion of healthy skin [2,4,5]. Although there exist no randomized controlled trials to initiate a timely antimycotic prophylaxis in burn patients, a lower threshold may decrease the risk of fatal fungal sepsis. Contra-arguments may be the possible

development of antimycotic resistances and increasing costs.

Available antimycotic substances such as echinocandins and triazoles show advantages compared to classic imidazol-based azoles and polyenes concerning efficacy, specificity, toxicity profile and patient comfort. Promising results are to be expected by candida-secretoric aspartic proteases (SAPs) inhibitors and calcineurin signaling pathway blockers [6].

However, despite the introduction of new antimycotic substances, some fungal organisms preserving angioinvasive and proteolytic potential, still require radical surgical therapy to provide a chance for survival. The restoration of immune resistance, early surgical therapy and early wound closure gain a key function in limiting the risk of fungal infection in burn patients [2,3,5].

Fungal infections should not be underestimated in modern burn care.

Abbreviations

SAPs: secretoric aspartic proteases; SIRS: severe inflammatory response syndrome

Competing interests

The author declares that they have no competing interests.

Acknowledgements

The author would like to thank PD Dr Michael Steen, Director of the Department of Plastic and Hand Surgery, Burn Trauma Center, Bergmannstrost Hospital, Halle (Saale), Germany, for his general support.

References

1. Dries DJ: **Management of burn injuries - recent developments in resuscitation, infection control and outcomes research.** *Scand J Trauma Resusc Emerg Med* 2009, **17**(1):14.
2. Ballard J, Edelman L, Saffle J, Sheridan R, Kagan R, Cancio L, Cairns B, Baker R, Fillari P, Wibbenmeyer L, Voight D, Palmieri T, Greenhalgh D, Kemakyan N, Caruso D, Multicenter Trials Group, American Burns Association: **Positive fungal cultures in burn patients: a multicenter review.** *J Burn Care Res* 2008, **29**:213-221.
3. Greenhalgh DG, Saffle JR, Holmes JH 4th, Gamelli RL, Palmieri TL, Horton JW, Tompkins RG, Traber DL, Mozingo DW, Deitch EA, Goodwin CW, Herndon DN, Gallagher JJ, Sanford AP, Jeng JC, Ahrnholz DH, Neely AN, O'Mara MS, Wolf SE, Purdue GF, Garner WL, Yowler CJ, Latenser BA, American Burn Association Consensus Conference on Burn Sepsis and Infection Group: **American Burns Association Consensus Conference to define sepsis and infection in burns.** *J Burn Care Res* 2007, **28**:776-790.
4. Murray CK, Loo FL, Hospenthal DR, Cancio LC, Jones JA, Kim SH, Holcomb JB, Wade CE, Wolf SE: **Incidence of systemic fungal infection and related mortality following severe burns.** *Burns* 2008, **34**:1108-1112.
5. Mathew BP, Nath M: **Recent approaches to antifungal therapy for invasive mycoses.** *ChemMedChem* 2009, **4**:310-323.
6. Horvath EE, Murray CK, Vaughan GM, Chung KK, Hospenthal DR, Wade CE, Holcomb JB, Wolf SE, Mason AD Jr, Cancio LC: **Fungal wound infection (not colonization) is independently associated with mortality in burn patients.** *Ann Surg* 2007, **245**:978-985.

Publish with **BioMed Central** and every scientist can read your work free of charge

"BioMed Central will be the most significant development for disseminating the results of biomedical research in our lifetime."

Sir Paul Nurse, Cancer Research UK

Your research papers will be:

- available free of charge to the entire biomedical community
- peer reviewed and published immediately upon acceptance
- cited in PubMed and archived on PubMed Central
- yours — you keep the copyright

Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp

